ACRO Biomedical Price To Sales vs. Net Income
Taking into consideration ACRO Biomedical's profitability measurements, ACRO Biomedical Co may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in May. Profitability indicators assess ACRO Biomedical's ability to earn profits and add value for shareholders.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Please note, there is a significant difference between ACRO Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if ACRO Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACRO Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For ACRO Biomedical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ACRO Biomedical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ACRO Biomedical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ACRO Biomedical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ACRO Biomedical Co over time as well as its relative position and ranking within its peers.
ACRO |
ACRO Biomedical Net Income vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ACRO Biomedical's current stock value. Our valuation model uses many indicators to compare ACRO Biomedical value to that of its competitors to determine the firm's financial worth. ACRO Biomedical Co is number one stock in price to sales category among its peers. It also is number one stock in net income category among its peers making up about 28,734 of Net Income per Price To Sales. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ACRO Biomedical's earnings, one of the primary drivers of an investment's value.ACRO Net Income vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
ACRO Biomedical |
| = | 267.90 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
ACRO Biomedical |
| = | 7.7 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
ACRO Net Income Comparison
ACRO Biomedical is currently under evaluation in net income category among its peers.
ACRO Biomedical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ACRO Biomedical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ACRO Biomedical will eventually generate negative long term returns. The profitability progress is the general direction of ACRO Biomedical's change in net profit over the period of time. It can combine multiple indicators of ACRO Biomedical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana. Acro Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.
ACRO Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ACRO Biomedical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ACRO Biomedical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ACRO Biomedical's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in ACRO Biomedical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Use Investing Themes to Complement your ACRO Biomedical position
In addition to having ACRO Biomedical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Risk ETFs Thematic Idea Now
Target Risk ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in ACRO Pink Sheet
To fully project ACRO Biomedical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ACRO Biomedical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ACRO Biomedical's income statement, its balance sheet, and the statement of cash flows.